These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 24300046)

  • 21. Review: NAATs diagnose C difficile; vancomycin improves cure, and fidaxomicin reduces recurrence.
    Zar FA
    Ann Intern Med; 2016 Jul; 165(2):JC4. PubMed ID: 27429316
    [No Abstract]   [Full Text] [Related]  

  • 22. Fidaxomicin for the treatment of Clostridium difficile infections.
    Whitman CB; Czosnowski QA
    Ann Pharmacother; 2012 Feb; 46(2):219-28. PubMed ID: 22318930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fidaxomicin versus vancomycin for Clostridium difficile infection.
    Louie TJ; Miller MA; Mullane KM; Weiss K; Lentnek A; Golan Y; Gorbach S; Sears P; Shue YK;
    N Engl J Med; 2011 Feb; 364(5):422-31. PubMed ID: 21288078
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection.
    Venugopal AA; Johnson S
    Clin Infect Dis; 2012 Feb; 54(4):568-74. PubMed ID: 22156854
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?
    Cornely OA
    Clin Microbiol Infect; 2012 Dec; 18 Suppl 6():28-35. PubMed ID: 23121552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fidaxomicin--the new drug for Clostridium difficile infection.
    Vaishnavi C
    Indian J Med Res; 2015 Apr; 141(4):398-407. PubMed ID: 26112840
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection.
    Miller M
    Expert Opin Pharmacother; 2010 Jun; 11(9):1569-78. PubMed ID: 20446864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fidaxomicin for treatment of clostridium difficile-associated diarrhea and its potential role for prophylaxis.
    Hostler CJ; Chen LF
    Expert Opin Pharmacother; 2013 Aug; 14(11):1529-36. PubMed ID: 23683070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The search for effective treatment of Clostridium difficile infection.
    DuPont HL
    N Engl J Med; 2011 Feb; 364(5):473-5. PubMed ID: 21288079
    [No Abstract]   [Full Text] [Related]  

  • 30. Fidaxomicin: balancing evidence and economics.
    Stevens V; Onufrak N; Brown J
    Am J Health Syst Pharm; 2012 Jun; 69(11):931. PubMed ID: 22610024
    [No Abstract]   [Full Text] [Related]  

  • 31. An antimicrobial stewardship program's real-world experience with fidaxomicin for treatment of Clostridium difficile infection: a case series.
    Vargo CA; Bauer KA; Mangino JE; Johnston JE; Goff DA
    Pharmacotherapy; 2014 Sep; 34(9):901-9. PubMed ID: 24898525
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy of fidaxomicin in the treatment of Clostridium difficile infection in a real-world clinical setting: a Spanish multi-centre retrospective cohort.
    Fehér C; Múñez Rubio E; Merino Amador P; Delgado-Iribarren Garcia-Campero A; Salavert M; Merino E; Maseda Garrido E; Díaz-Brito V; Álvarez MJ; Mensa J
    Eur J Clin Microbiol Infect Dis; 2017 Feb; 36(2):295-303. PubMed ID: 27718071
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.
    Lancaster JW; Matthews SJ
    Clin Ther; 2012 Jan; 34(1):1-13. PubMed ID: 22284993
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful use of fidaxomicin in recurrent Clostridium difficile infection in a child.
    Smeltzer S; Hassoun A
    J Antimicrob Chemother; 2013 Jul; 68(7):1688-9. PubMed ID: 23463209
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison.
    Cornely OA; Nathwani D; Ivanescu C; Odufowora-Sita O; Retsa P; Odeyemi IA
    J Antimicrob Chemother; 2014 Nov; 69(11):2892-900. PubMed ID: 25074856
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clostridium difficile infecion--diagnostics, prevention and treatment].
    Piekarska M; Wandałowicz AD; Miigoć H
    Pol Merkur Lekarski; 2014 Apr; 36(214):278-82. PubMed ID: 24868904
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan.
    Mikamo H; Tateda K; Yanagihara K; Kusachi S; Takesue Y; Miki T; Oizumi Y; Gamo K; Hashimoto A; Toyoshima J; Kato K
    J Infect Chemother; 2018 Sep; 24(9):744-752. PubMed ID: 29934056
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fidaxomicin for treatment of Clostridium difficile infection in clinical practice: a prospective cohort study in a French University Hospital.
    Pichenot M; Héquette-Ruz R; Le Guern R; Grandbastien B; Charlet C; Wallet F; Schiettecatte S; Loeuillet F; Guery B; Galperine T
    Infection; 2017 Aug; 45(4):425-431. PubMed ID: 28120176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and economic benefits of fidaxomicin compared to vancomycin for Clostridium difficile infection.
    Gallagher JC; Reilly JP; Navalkele B; Downham G; Haynes K; Trivedi M
    Antimicrob Agents Chemother; 2015 Nov; 59(11):7007-10. PubMed ID: 26324268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fidaxomicin for the treatment of Clostridium difficile infections.
    Drug Ther Bull; 2012 Nov; 50(11):130-2. PubMed ID: 23154594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.